Live nieuws • May 05
Integer Holdings Considers Sale or Merger Following Q1 Profit and Lowered 2026 Outlook Integer reported income from continuing operations of $16.5 million in Q1 2026, compared with a prior-year loss of $22.5 million, alongside modest sales growth.
The board has launched a broad review of options including a potential sale, merger or business combination, supported by Goldman Sachs and Davis Polk & Wardwell.
Q1 2026 revenue and adjusted EPS were ahead of market expectations, but full-year 2026 revenue guidance was cut to about $1.82b and adjusted EPS guidance was lowered due to product rollout issues and revised customer demand.
For you as an investor, the key tension is between improved quarterly profitability and the more cautious outlook for the rest of 2026. Management pointed to three new product rollouts and updated customer demand forecasts as the main reasons for trimming guidance, along with a weaker operating margin compared with last year. The company also expects reported sales to be slightly lower for 2026, with organic sales flat to down 1%, tied to temporary normalization in the electrophysiology market rather than contract losses or supply changes.
At the same time, the board’s decision to review “all potential opportunities” reflects external interest in the business and a willingness to consider structural changes. This process can introduce uncertainty around execution, stock price volatility and potential impacts on the balance sheet, and there is no timeline or assurance that a transaction will occur. Investors may want to watch for updates on the review, further commentary on the electrophysiology market, and progress on integrating the three tuck-in acquisitions completed since early 2025. Aankondiging • May 03
Integer Holdings Corporation Announces Earnings Guidance for the Year 2026 Integer Holdings Corporation announced earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,805 million to $1,835 million decrease of 3% to 1% as compared to previous year, operating income in the range of $165 million to $185 million decrease of 25% to 16% as compared to previous year, net income in the range of $105 million to $125 million increase of 2% to 21% as compared to previous year, and diluted earnings per share in the range of $3.07 to $3.64 increase of 6% to 26% as compared to previous year. Reported Earnings • May 01
First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2026 results: EPS: US$0.48 (up from US$0.66 loss in 1Q 2025). Revenue: US$439.6m (flat on 1Q 2025). Net income: US$16.5m (up US$39.0m from 1Q 2025). Profit margin: 3.8% (up from net loss in 1Q 2025). Revenue exceeded analyst estimates by 3.2%. Earnings per share (EPS) missed analyst estimates by 26%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Aankondiging • Apr 08
Integer Holdings Corporation, Annual General Meeting, May 20, 2026 Integer Holdings Corporation, Annual General Meeting, May 20, 2026. Location: hilton dallas/plano granite park hotel, 5805 granite parkway, plano, plano United States Aankondiging • Apr 07
Integer Holdings Corporation Announces Pamela G. Bailey, Independent Chair of the Board Will Not Stand for Re-Election At 2026 AGM Integer Holdings Corporation announced Pamela G. Bailey, who currently serves as Integer’s independent Chair of the Board, will not stand for re-election at the Company’s 2026 Annual Meeting of Stockholders, scheduled for May 20, 2026. Aankondiging • Apr 02
Integer Holdings Corporation to Report Q1, 2026 Results on Apr 30, 2026 Integer Holdings Corporation announced that they will report Q1, 2026 results Pre-Market on Apr 30, 2026 Aankondiging • Mar 12
Integer Holdings Corporation Announces Board Changes, Effective March 12, 2026 Integer Holdings Corporation has appointed two new directors to its Board of Directors: James F. Flanagan and Aaron Kapito. These appointments are effective as of March 12, 2026, and the board size has been increased to 13 members. The Cooperation Agreement also stipulates that two incumbent directors will not stand for re-election at the 2026 Annual Meeting of Stockholders. The agreement includes provisions for the appointment of the new directors to specific board committees, including the Audit Committee, the Compensation and Organization Committee, and the Technology Strategy Committee. The Cooperation Agreement includes voting commitments, standstill restrictions, and mutual non-disparagement provisions, which remain in place until the earlier of 30 days prior to the advance notice deadline for the 2027 Annual Meeting or one year from the effective date of the agreement. Mr. Flanagan is the former Chief Operating Officer of PwC from 2014 to 2021, bringing proven diversified, strategic, operational and qualified financial expertise through 39 years of increasing client and management roles. Previously, he also served as PwC’s US Financial Services Practice Leader from 2006 to 2014, and prior to that as the Transaction Services Leader from 2001 to 2006 and Transaction Services Partner from 1994 to 2001. He has served on the Board of Directors at Belami Ecommerce, a subsidiary of SkyX Platforms Corp. from 2022 to 2025, while also serving as Audit Committee Chair. Mr. Flanagan received a B.S. in Accounting from the C.W. Post School of Professional Accountancy at Long Island University. Mr. Kapito is a Partner at Politan Capital Management L.P., an investment management firm that he co-founded in 2021. Previously, Mr. Kapito served as a Senior Analyst at Lion Point Capital from 2018 to 2021, a Senior Analyst and founding member of Delonix Capital from 2016 to 2017, and an Associate Portfolio Manager for Elliott Management L.P. from 2011 to 2016. Mr. Kapito currently serves on the boards of Rocky Mountain Steel Mills, a manufacturer of high-performance steel products, and Associated Veterinary Partners, a veterinary clinic platform. Mr. Kapito received a B.S. in Economics from the Wharton School at the University of Pennsylvania and an M.B.A. from Harvard Business School. Recent Insider Transactions Derivative • Mar 03
CEO, President & Director exercised options and sold US$1.5m worth of stock On the 24th of February, Payman Khales exercised options to acquire 17k shares at no cost and sold these for an average price of US$87.10 per share. This trade did not impact their existing holding. For the year to December 2019, Payman's total compensation was 28% salary and 72% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2025, Payman's direct individual holding has increased from 19.74k shares to 25.47k. Company insiders have collectively sold US$13m more than they bought, via options and on-market transactions in the last 12 months. New Risk • Feb 22
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 42% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results. Price Target Changed • Feb 22
Price target increased by 7.4% to US$91.88 Up from US$85.57, the current price target is an average from 8 analysts. New target price is 8.3% above last closing price of US$84.85. Stock is down 35% over the past year. The company is forecast to post earnings per share of US$4.19 for next year compared to US$2.96 last year. Reported Earnings • Feb 20
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: US$2.96 (down from US$3.60 in FY 2024). Revenue: US$1.85b (up 8.0% from FY 2024). Net income: US$102.8m (down 15% from FY 2024). Profit margin: 5.5% (down from 7.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.3%. Revenue is forecast to grow 4.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Aankondiging • Feb 19
Integer Holdings Corporation Provides Earnings Guidance for the Year 2026 Integer Holdings Corporation provided earnings guidance for the year 2026. For the year, the company expects as reported sales in the range of $1,826 million to $1,876 million, operating income in the range of $184 million to $204 million, net income in the range of $121 million to $138 million, and diluted earnings per share in the range of $3.53 to $4.01. Aankondiging • Jan 28
Integer Holdings Corporation to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During Md&M West 2026 Integer Holdings Corporation will exhibit during MD&M West 2026 in Anaheim, Calif., Feb. 3 - 5. Integer will unveil a significantly expanded 20 x 50 sq. ft. new booth #3201, showcasing the company's full range of customer solutions. On prominent display will be R&D Velocity, Integer's integrated R&D ecosystem connecting design, prototyping and manufacturing to help medical device companies develop products that are manufacturable from the start, accelerating the time between design and manufacturability. The company will showcase several solutions - delivered through a network of locations globally - that are central to R&D Velocity, including: Differentiated Technology Platforms: Proven product technologies that enable, accelerate and de-risk the development of customers' next generation devices. Global Capabilities and Expertise: Specialized labs and integrated manufacturing all in one ecosystem along with dedicated engineers and global centers of excellence to accelerate every phase of development. Ease of Manufacturability: Designs optimized early to scale seamlessly, reducing rework and accelerating launch. Rapid Prototyping: Engineer-to-engineer collaboration delivering prototypes in as little as two weeks. Integer will additionally highlight a range of key product areas and innovations during MD&M West, including: Integer Medical Coatings: The company continues to expand its role as a fully integrated coating partner for medical devices, strengthening its ability to deliver end-to-end surface-modification solutions. Integer will also showcase its full coatings portfolio, including PTFE, PTFE alternatives, hydrophilic coatings, parylene, and advanced surface-modification technologies. Following the acquisitions of Precision Coating,VSi Parylene, and certain Biocoat assets last year, Integer has further strengthened its position as a fully integrated coating partner For medical devices. Cardiac Rhythm Management and Neuromodulation: Miniaturized technologies for finished IPG systems, as well as Gen 3 Li-Ion and Gen 2 CFx batteries. Cardio and Vascular: A full range of electrophysiology, structural heart, and neurovascular product solutions including complex catheters, guidewires, steerable introducers and sheaths, therapy delivery systems and implant technologies. Aankondiging • Jan 22
Integer Holdings Corporation to Report Q4, 2025 Results on Feb 19, 2026 Integer Holdings Corporation announced that they will report Q4, 2025 results Pre-Market on Feb 19, 2026 Aankondiging • Dec 11
Saxena White P.A. Files Securities Fraud Class Action Against Integer Holdings Corporation and Certain of its Executives Saxena White P.A. has filed a securities fraud class action lawsuit (the “Class Action”) in the United States District Court for the Southern District of New York against Integer Holdings Corporation (“Integer” or the “Company”) and certain of its executive officers (collectively, “Defendants”). The Class Action asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and U.S. Securities and Exchange Commission (“SEC”) Rule 10b-5 promulgated thereunder on behalf of all persons or entities that purchased Integer common stock between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Saxena White is captioned West Palm Beach Firefighters’ Pension Fund v. Integer Holdings Corporation, et al., No. 25-cv-10251 (S.D.N.Y.).Based in Plano, Texas, Integer purports to be one of the medical device contract development and manufacturing organizations in the world. The Company contracts with medical device companies to manufacture cardiac rhythm management and cardio and vascular (“C&V”) medical devices. Integer’s C&V product line generates approximately 60% of the Company’s total revenue. As a part of the C&V product line, Integer manufactures electrophysiology (“EP”) devices, which diagnose and map the heart’s electrical activity to address problems such as irregular heartbeats (cardiac arrhythmias).Prior to the Class Period, EP devices underwent a technological revolution as Integer customers began to develop devices for pulse field ablation (“PFA”) procedures that use brief, high-energy electrical pulses to treat atrial fibrillation. In turn, the industry became increasingly focused on integrating EP devices and PFA platforms to effectuate a more seamless cardiac procedure. As a result, EP devices represented a significant growth driver for Integer’s C&V segment. Leading up to the Class Period, CEO Dziedzic described PFA platforms as “a tailwind” due to the Company’s “vertically integrated offering[,]” while also touting that Integer “benefit[ed] significantly from electrophysiology procedure growth.” CEO Dziedzic further explained, “We participate in the full procedure, which is one of the strengths of Integer.” The Class Action alleges that, during the Class Period, Defendants made materially false and/or misleading statements and failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose that: (1) Integer materially overstated its competitive position within the growing EP manufacturing market; (2) despite Integer’s claims of strong visibility into customer demand, the Company was experiencing a sustained deterioration in sales relating to two of its EP devices; (3) in turn, Integer mischaracterized its EP devices as a long-term growth driver for the Company’s C&V segment; (4) as a result of the above, Defendants’ positive statements about the Company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. Aankondiging • Nov 05
Integer Holdings Corporation (NYSE:ITGR) announces an Equity Buyback for $200 million worth of its shares. Integer Holdings Corporation (NYSE:ITGR) announces a share repurchase program. Under the program, the company will repurchase up to $200 million worth of its common stock. The company intends to primarily utilize cash on hand and free cash flows to fund the share repurchase program. The program has no expiration date. Buy Or Sell Opportunity • Oct 30
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 41% to US$63.32. The fair value is estimated to be US$80.00, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 13%. Revenue is forecast to grow by 5.6% in 2 years. Earnings are forecast to grow by 106% in the next 2 years. Reported Earnings • Oct 24
Third quarter 2025 earnings: EPS misses analyst expectations Third quarter 2025 results: EPS: US$1.13 (up from US$1.08 in 3Q 2024). Revenue: US$467.7m (up 8.4% from 3Q 2024). Net income: US$39.7m (up 9.4% from 3Q 2024). Profit margin: 8.5% (up from 8.4% in 3Q 2024). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 7.0%. Revenue is forecast to grow 3.8% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Price Target Changed • Oct 24
Price target decreased by 38% to US$86.00 Down from US$139, the current price target is an average from 7 analysts. New target price is 18% above last closing price of US$72.91. Stock is down 42% over the past year. The company is forecast to post earnings per share of US$2.80 for next year compared to US$3.60 last year. Aankondiging • Sep 25
Integer Holdings Corporation to Report Q3, 2025 Results on Oct 23, 2025 Integer Holdings Corporation announced that they will report Q3, 2025 results Pre-Market on Oct 23, 2025 Aankondiging • Jul 11
Integer Holdings Corporation Appoints Michael Coyle to Board of Directors Integer Holdings Corporation announced it has appointed Michael Coyle to its Board of Directors. Coyle brings more than 40 years of leadership in the medical device industry to Integer and joins the Board as a member of the Audit Committee, Compensation & Organization Committee, and Technology Strategy Committee. He most recently served as president and CEO of iRhythm Technologies. Before that, he was executive vice president and group president of Medtronic’s cardio and vascular group and held leadership roles at St. Jude Medical and Eli Lilly earlier in his career. Coyle is currently a director on the Haemonetics Corporation and BaroPace boards and previously held positions on the boards of VNUS Medical Technologies Inc. and Volcano Corporation. He earned a master's degree in business administration from the Wharton School of Business, University of Pennsylvania, and a bachelor's degree from Case Western Reserve University. He additionally holds six U.S. patents related to cardiovascular medical device products and technologies. Aankondiging • Jun 26
Integer Holdings Corporation to Report Q2, 2025 Results on Jul 24, 2025 Integer Holdings Corporation announced that they will report Q2, 2025 results at 8:00 AM, US Eastern Standard Time on Jul 24, 2025 Recent Insider Transactions Derivative • Jun 05
Independent Director notifies of intention to sell stock Donald Spence intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 4th of June. If the sale is conducted around the recent share price of US$120, it would amount to US$1.8m. Since March 2025, Donald has owned 18.78k shares directly. Company insiders have collectively sold US$12m more than they bought, via options and on-market transactions in the last 12 months. Buy Or Sell Opportunity • May 28
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 3.6% to US$119. The fair value is estimated to be US$151, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 166% in the next 2 years. Buy Or Sell Opportunity • Apr 30
Now 20% undervalued after recent price drop Over the last 90 days, the stock has fallen 12% to US$126. The fair value is estimated to be US$158, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 15%. Revenue is forecast to grow by 17% in 2 years. Earnings are forecast to grow by 166% in the next 2 years. New Risk • Apr 27
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 36% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Large one-off items impacting financial results. Reported Earnings • Apr 25
First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2025 results: US$0.66 loss per share (down from US$0.61 profit in 1Q 2024). Revenue: US$437.4m (up 5.4% from 1Q 2024). Net loss: US$22.5m (down 210% from profit in 1Q 2024). Revenue exceeded analyst estimates by 2.0%. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 6.7% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 18% per year. Aankondiging • Apr 25
Integer Holdings Corporation Provides Earnings Guidance for the Year 2025 Integer Holdings Corporation provided earnings guidance for the year 2025. For the year, the company expects sales in the range of $1,846 million to $1,880 million, Operating income in the range of $242 million to $258
million, Income from continuing operations of $108 million to $120 million, Diluted earnings per share in the range of $3.00 to $3.36. Buy Or Sell Opportunity • Apr 08
Now 23% undervalued after recent price drop Over the last 90 days, the stock has fallen 20% to US$107. The fair value is estimated to be US$138, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 15%. For the next 3 years, revenue is forecast to grow by 6.7% per annum. Earnings are also forecast to grow by 19% per annum over the same time period. Aankondiging • Mar 27
Integer Holdings Corporation to Report Q1, 2025 Results on Apr 24, 2025 Integer Holdings Corporation announced that they will report Q1, 2025 results at 8:00 AM, Eastern Standard Time on Apr 24, 2025 Aankondiging • Mar 19
Integer Holdings Corporation, Annual General Meeting, May 21, 2025 Integer Holdings Corporation, Annual General Meeting, May 21, 2025. Location: 5830 granite parkway, suite 1150, plano, texas 75024, United States Recent Insider Transactions Derivative • Mar 14
President exercised options and sold US$1.6m worth of stock On the 11th of March, Joseph Dziedzic exercised options to acquire 13k shares at no cost and sold these for an average price of US$120 per share. This trade did not impact their existing holding. For the year to December 2018, Joseph's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Joseph's direct individual holding has increased from 222.32k shares to 291.78k. Company insiders have collectively sold US$9.7m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 20
Full year 2024 earnings: EPS misses analyst expectations Full year 2024 results: EPS: US$3.60 (up from US$2.72 in FY 2023). Revenue: US$1.72b (up 7.5% from FY 2023). Net income: US$121.1m (up 34% from FY 2023). Profit margin: 7.1% (up from 5.7% in FY 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 8.5%. Revenue is forecast to grow 6.4% p.a. on average during the next 3 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 15% per year whereas the company’s share price has increased by 17% per year. Aankondiging • Feb 05
Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million. Integer Holdings Corporation (NYSE:ITGR) acquired Substantially All Assets of Precision Coating Company, Inc. for approximately $150 million on January 7, 2025. A cash consideration of $152 million will be paid by Integer Holdings Corporation, subject to adjustment for additional contingent consideration. As part of consideration, $152 million is paid towards assets of Substantially All Assets of Precision Coating Company, Inc.
Integer Holdings Corporation (NYSE:ITGR) completed the acquisition of Substantially All Assets of Precision Coating Company, Inc. on January 7, 2025. Piper Sandler Companies (NYSE:PIPR) acted as financial advisor to Precision Coating Company, Inc. Recent Insider Transactions Derivative • Jan 24
President exercised options and sold US$1.1m worth of stock On the 21st of January, Joseph Dziedzic exercised options to acquire 8k shares at no cost and sold these for an average price of US$142 per share. This trade did not impact their existing holding. For the year to December 2018, Joseph's total compensation was 14% salary and 86% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2024, Joseph's direct individual holding has increased from 222.32k shares to 224.21k. Company insiders have collectively sold US$8.1m more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Jan 23
Integer Holdings Corporation to Report Q4, 2024 Results on Feb 20, 2025 Integer Holdings Corporation announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 20, 2025 Recent Insider Transactions Derivative • Jan 07
Key Executive exercised options and sold US$376k worth of stock On the 3rd of January, John Harris exercised options to acquire 3k shares at no cost and sold these for an average price of US$134 per share. This trade did not impact their existing holding. Since March 2024, John's direct individual holding has increased from 1.47k shares to 1.52k. Company insiders have collectively sold US$7.5m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Oct 24
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2024 results: EPS: US$1.08 (up from US$0.82 in 3Q 2023). Revenue: US$431.4m (up 6.6% from 3Q 2023). Net income: US$36.3m (up 33% from 3Q 2023). Profit margin: 8.4% (up from 6.7% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 2.1%. Earnings per share (EPS) exceeded analyst estimates by 4.8%. Revenue is forecast to grow 6.6% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 9% per year whereas the company’s share price has increased by 11% per year. Aankondiging • Sep 27
Integer Holdings Corporation to Report Q3, 2024 Results on Oct 24, 2024 Integer Holdings Corporation announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Oct 24, 2024 Recent Insider Transactions • Aug 02
Independent Director recently sold US$551k worth of stock On the 31st of July, Jean Hobby sold around 5k shares on-market at roughly US$120 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$992k. Insiders have been net sellers, collectively disposing of US$2.9m more than they bought in the last 12 months. Recent Insider Transactions Derivative • Aug 01
Key Executive notifies of intention to sell stock John Harris intends to sell 3k shares in the next 90 days after lodging an Intent To Sell Form on the 30th of July. If the sale is conducted around the recent share price of US$124, it would amount to US$421k. Since March 2024, John's direct individual holding has increased from 1.47k shares to 4.92k. Company insiders have collectively sold US$5.0m more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Jul 26
Second quarter 2024 earnings: EPS exceeds analyst expectations Second quarter 2024 results: EPS: US$0.93 (up from US$0.72 in 2Q 2023). Revenue: US$436.2m (up 9.0% from 2Q 2023). Net income: US$31.2m (up 30% from 2Q 2023). Profit margin: 7.2% (up from 6.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 3.8%. Revenue is forecast to grow 6.8% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 6% per year. Aankondiging • Jul 26
Integer Holdings Corporation Provides Earnings Guidance for the Year 2024 Integer Holdings Corporation provided earnings guidance for the year 2024. For the year, the company expects sales in the range of $1,735 million to $1,770 million, Operating income in the range of $202 million to $220 million, Net income in the range of $116 million to $130 million, Diluted earnings per share in the range of $3.26 to $3.67.